HK1188454A1 - 咪唑並 喹啉- -酮化合物及其作為 激酶/ 雙重抑制劑的用途 - Google Patents
咪唑並 喹啉- -酮化合物及其作為 激酶/ 雙重抑制劑的用途Info
- Publication number
- HK1188454A1 HK1188454A1 HK14101571.9A HK14101571A HK1188454A1 HK 1188454 A1 HK1188454 A1 HK 1188454A1 HK 14101571 A HK14101571 A HK 14101571A HK 1188454 A1 HK1188454 A1 HK 1188454A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- mtor
- quinolin
- imidazo
- kinase
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161432958P | 2011-01-14 | 2011-01-14 | |
PCT/US2012/020897 WO2012097039A1 (en) | 2011-01-14 | 2012-01-11 | Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1188454A1 true HK1188454A1 (zh) | 2014-05-02 |
Family
ID=45531593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK14101571.9A HK1188454A1 (zh) | 2011-01-14 | 2014-02-19 | 咪唑並 喹啉- -酮化合物及其作為 激酶/ 雙重抑制劑的用途 |
Country Status (39)
Country | Link |
---|---|
US (2) | US8440829B2 (zh) |
EP (1) | EP2663564B1 (zh) |
JP (1) | JP5891247B2 (zh) |
KR (1) | KR101561360B1 (zh) |
CN (1) | CN103282364B (zh) |
AR (1) | AR084551A1 (zh) |
AU (1) | AU2012205619B2 (zh) |
BR (1) | BR112013017672A2 (zh) |
CA (1) | CA2824760C (zh) |
CL (1) | CL2013002005A1 (zh) |
CO (1) | CO6731133A2 (zh) |
CR (1) | CR20130289A (zh) |
CY (1) | CY1116007T1 (zh) |
DK (1) | DK2663564T3 (zh) |
DO (1) | DOP2013000158A (zh) |
EA (1) | EA022163B1 (zh) |
EC (1) | ECSP13012764A (zh) |
ES (1) | ES2531891T3 (zh) |
GT (1) | GT201300180A (zh) |
HK (1) | HK1188454A1 (zh) |
HR (1) | HRP20150135T1 (zh) |
HU (1) | HUE024426T2 (zh) |
IL (1) | IL227165A (zh) |
JO (1) | JO3003B1 (zh) |
ME (1) | ME02019B (zh) |
MX (1) | MX2013008185A (zh) |
MY (1) | MY164705A (zh) |
PE (1) | PE20140864A1 (zh) |
PL (1) | PL2663564T3 (zh) |
PT (1) | PT2663564E (zh) |
RS (1) | RS53828B1 (zh) |
SG (1) | SG191744A1 (zh) |
SI (1) | SI2663564T1 (zh) |
SV (1) | SV2013004496A (zh) |
TN (1) | TN2013000237A1 (zh) |
TW (1) | TWI518086B (zh) |
UA (1) | UA109921C2 (zh) |
WO (1) | WO2012097039A1 (zh) |
ZA (1) | ZA201304757B (zh) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
US9050345B2 (en) | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
US20160264570A1 (en) * | 2013-11-15 | 2016-09-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Method of blocking transmission of malarial parasite |
TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
TW201703769A (zh) | 2015-05-08 | 2017-02-01 | 美國禮來大藥廠 | 用於癌症的組合療法 |
GB201516504D0 (en) * | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
AU2016370297A1 (en) * | 2015-12-15 | 2018-05-24 | Eli Lilly And Company | Combination therapy for cancer |
WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
RU2754452C2 (ru) * | 2016-04-12 | 2021-09-02 | Эли Лилли Энд Компани | Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака |
CN109310684B (zh) | 2016-04-12 | 2021-11-19 | 伊莱利利公司 | 用于治疗癌症的notch和cdk4/6抑制剂的组合疗法 |
IL263110B (en) | 2016-05-20 | 2022-07-01 | Lilly Co Eli | Combined treatment of notch and pd-1 or pd-l1 inhibitors |
WO2018017410A1 (en) | 2016-07-22 | 2018-01-25 | Eli Lilly And Company | Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer |
WO2018063873A1 (en) | 2016-09-27 | 2018-04-05 | Eli Lilly And Company | Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of pancreatic cancer |
US11376259B2 (en) | 2016-10-12 | 2022-07-05 | Eli Lilly And Company | Targeted treatment of mature T-cell lymphoma |
CN110461335A (zh) | 2017-02-17 | 2019-11-15 | 弗雷德哈钦森癌症研究中心 | 用于治疗bcma相关癌症和自身免疫性失调的联合疗法 |
US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
CN110386932A (zh) | 2018-04-20 | 2019-10-29 | 艾科思莱德制药公司 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
DK3813946T3 (da) | 2018-06-15 | 2024-08-19 | Janssen Pharmaceutica Nv | Rapamycin-analoger og anvendelser deraf |
WO2020081329A1 (en) * | 2018-10-18 | 2020-04-23 | Camp4 Therapeutics Corporation | Methods and compositions for modulating pcsk9 and angptl3 expression |
CN115209897A (zh) | 2019-12-05 | 2022-10-18 | 安纳库利亚治疗公司 | 雷帕霉素类似物及其用途 |
ES2974742T3 (es) | 2020-09-21 | 2024-07-01 | Wei Zhong | Compuestos de 1-(3,3-difluoropiperidin-4-il)-imidazo[4,5-c]quinolin-2-ona sustituidos con capacidad de penetración en la barrera hematoencefálica |
EP3992191A1 (en) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
MXPA06005702A (es) | 2003-11-21 | 2006-08-17 | Novartis Ag | Derivados de 1h-imidazoquinolina como inhibidores de quinasa de proteina. |
AR046845A1 (es) * | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
JP2008531567A (ja) * | 2005-02-23 | 2008-08-14 | コーリー ファーマシューティカル グループ,インコーポレイテッド | ヒドロキシアルキル置換イミダゾキノリン化合物および方法 |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
WO2007056112A2 (en) | 2005-11-04 | 2007-05-18 | Coley Pharmaceutical Group, Inc. | Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods |
WO2007106854A2 (en) | 2006-03-15 | 2007-09-20 | Coley Pharmaceutical Group, Inc. | Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods |
ES2614130T3 (es) | 2008-09-30 | 2017-05-29 | Pfizer Inc. | Compuestos de imidazo[1,5]naftiridina, su uso farmacéutico y composiciones |
WO2010139747A1 (en) | 2009-06-04 | 2010-12-09 | Novartis Ag | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
JP5596137B2 (ja) | 2009-06-04 | 2014-09-24 | ノバルティス アーゲー | 1H−イミダゾ[4,5−c]キノリノン誘導体 |
JP2012532187A (ja) * | 2009-06-30 | 2012-12-13 | ピラマル・ライフ・サイエンシーズ・リミテッド | イミダゾ[4,5−c]キノリン誘導体ならびに腫瘍および/または炎症の治療におけるそれらの使用 |
MX2013006284A (es) * | 2010-12-06 | 2013-10-28 | Piramal Entpr Ltd | Derivados sustituidos de imidazoquinolina. |
JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
-
2011
- 2011-12-20 JO JOP/2011/0389A patent/JO3003B1/ar active
- 2011-12-22 AR ARP110104894A patent/AR084551A1/es unknown
- 2011-12-23 TW TW100148428A patent/TWI518086B/zh not_active IP Right Cessation
-
2012
- 2012-01-11 RS RS20150095A patent/RS53828B1/en unknown
- 2012-01-11 KR KR1020137018235A patent/KR101561360B1/ko active IP Right Grant
- 2012-01-11 ES ES12701207.8T patent/ES2531891T3/es active Active
- 2012-01-11 PT PT127012078T patent/PT2663564E/pt unknown
- 2012-01-11 JP JP2013549509A patent/JP5891247B2/ja not_active Expired - Fee Related
- 2012-01-11 BR BR112013017672A patent/BR112013017672A2/pt not_active Application Discontinuation
- 2012-01-11 DK DK12701207.8T patent/DK2663564T3/en active
- 2012-01-11 CA CA2824760A patent/CA2824760C/en not_active Expired - Fee Related
- 2012-01-11 WO PCT/US2012/020897 patent/WO2012097039A1/en active Application Filing
- 2012-01-11 PE PE2013001553A patent/PE20140864A1/es active IP Right Grant
- 2012-01-11 HU HUE12701207A patent/HUE024426T2/en unknown
- 2012-01-11 EP EP12701207.8A patent/EP2663564B1/en active Active
- 2012-01-11 MY MYPI2013701219A patent/MY164705A/en unknown
- 2012-01-11 AU AU2012205619A patent/AU2012205619B2/en not_active Ceased
- 2012-01-11 EA EA201390823A patent/EA022163B1/ru not_active IP Right Cessation
- 2012-01-11 PL PL12701207T patent/PL2663564T3/pl unknown
- 2012-01-11 US US13/347,886 patent/US8440829B2/en not_active Expired - Fee Related
- 2012-01-11 ME MEP-2015-14A patent/ME02019B/me unknown
- 2012-01-11 CN CN201280005256.0A patent/CN103282364B/zh not_active Expired - Fee Related
- 2012-01-11 MX MX2013008185A patent/MX2013008185A/es active IP Right Grant
- 2012-01-11 SI SI201230117T patent/SI2663564T1/sl unknown
- 2012-01-11 SG SG2013047311A patent/SG191744A1/en unknown
- 2012-11-01 UA UAA201308519A patent/UA109921C2/ru unknown
-
2013
- 2013-04-16 US US13/863,411 patent/US8658668B2/en not_active Expired - Fee Related
- 2013-06-03 TN TNP2013000237A patent/TN2013000237A1/fr unknown
- 2013-06-14 CR CR20130289A patent/CR20130289A/es unknown
- 2013-06-24 IL IL227165A patent/IL227165A/en active IP Right Grant
- 2013-06-25 ZA ZA2013/04757A patent/ZA201304757B/en unknown
- 2013-07-01 DO DO2013000158A patent/DOP2013000158A/es unknown
- 2013-07-09 CL CL2013002005A patent/CL2013002005A1/es unknown
- 2013-07-11 GT GT201300180A patent/GT201300180A/es unknown
- 2013-07-12 SV SV2013004496A patent/SV2013004496A/es unknown
- 2013-07-12 EC ECSP13012764 patent/ECSP13012764A/es unknown
- 2013-07-25 CO CO13176485A patent/CO6731133A2/es unknown
-
2014
- 2014-02-19 HK HK14101571.9A patent/HK1188454A1/zh not_active IP Right Cessation
-
2015
- 2015-01-30 CY CY20151100096T patent/CY1116007T1/el unknown
- 2015-02-04 HR HRP20150135AT patent/HRP20150135T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1188454A1 (zh) | 咪唑並 喹啉- -酮化合物及其作為 激酶/ 雙重抑制劑的用途 | |
HRP20171724T1 (hr) | Imidazo[1,2-b]piridazin derivati kao inhibitori kinaze | |
EP2945632A4 (en) | HETEROBICCLOSUBSTITUTED [1,2,4] TRIAZOLO [1,5-C] CHINAZOLINE-5-AMINE COMPOUNDS WITH A2A ANTAGONISTIC PROPERTIES | |
HK1184154A1 (zh) | 作為 抑制劑的咪唑並 喹啉類化合物 | |
EP2608669A4 (en) | NEW PYRAZOLO- [1,5-A-] PYRIMIDINE DERIVATIVES AS ANTI-MTOR HEMMER | |
AP3709A (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts | |
AU2008228964A8 (en) | Pyrazolopyrimidine Analogs and their use as mTOR kinase and PI3 kinase inhibitors | |
EP2525659A4 (en) | PYRAZOLO [1,5-A] PYRIMIDINES COMPOUNDS AS MTOR INHIBITORS | |
IL228435A0 (en) | Use of 3,2-dihydroimidase [2,1-c]converted quinazolines | |
EP2739627A4 (en) | 2,3-DIHYDROIMIDAZO [1,2-C] PYRIMIDIN-5 (1H) -ONE COMPOUNDS AND USE AS INHIBITORS OF LP-PLA2 | |
IL229993A (en) | 8 - Alkoxy [1,2,4] triazolo [5,1 – c] pyrimidine– 2 | |
EP2938344A4 (en) | PIPERAZINE-SUBSTITUTED [1,2,4] TRIAZOLO [1,5-C] QUINAZOLINE-5-AMINE COMPOUNDS WITH A2A ANTAGONISTIC PROPERTIES | |
IL221479A0 (en) | Triazolo [4,5-b] pyridin derivatives | |
EP2719697A4 (en) | PYRIDONAPHTHYRIDINE PI3K / MTOR DUALHEMMER AND THE PREPARATION AND USE THEREOF | |
EP2651937B8 (en) | Imidazo[4,5-c]quinolin-1-yl derivative useful in therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20210114 |